EBIT at other companies
Other financials
Where this comes from
Calculated from Relmada Therapeutics, Inc.’s reported figures.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s EBIT?
- Relmada Therapeutics, Inc. (RLMD) reported EBIT of -$19.46M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s EBIT changed year-over-year?
- Relmada Therapeutics, Inc.'s EBIT decreased by 6.8% year-over-year, from -$18.22M to -$19.46M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s EBIT has grown at a -17.2% compound annual growth rate (CAGR), from -$125.7M to -$59.1M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.